A 4-alkynylimidazole derivative represented by the general formula or a pharmaceutically acceptable salt thereof: [wherein ring A is a cyclohexyl substituted by E at the 4-position or a phenyl substituted by E at the 4-position; ring B is cycloalkyl, aryl or heteroaryl; m is an integer of any one of 0∼2; n is an integer of any one of 1∼3; R 1 is a hydrogen atom, a C 1 ∼C 4 alkyl group, a C 1 ∼C 4 alkoxy group, a halogen atom, or a C 1 ∼C 4 haloalkyl group; R 2 and R 3 are each independently a hydrogen atom, a halogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the carbon atom to which R 2 and R 3 are adjacent, form a C 3 ∼C 6 carbon ring; R 4 and R 5 are each independently a hydrogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the carbon atom to which R 4 and R 5 are adjacent, form a C 3 ∼C 6 carbon ring, and R 6 and R 7 are each independently a hydrogen atom, a C 1 ∼C 4 alkyl group, a C 1 ∼C 4 alkoxy group, a C 1 ∼C 4 hydroxyalkyl group, a carboxyl group, a cyano group, a halogen atom, a C 1 ∼C 4 haloalkyl group, or a C 1 ∼C 4 haloalkoxy group; X is -OR 8, -NR 9 R 10 or a halogen atom; R 8 is a hydrogen atom, a C 1 ∼C 4 alkyl group or a C 1 ∼C 4 haloalkyl group; R 9 and R 10 are each independently a hydrogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the nitrogen atom to which R 9 and R 10 are adjacent, form a nitrogen-containing heterocycle, Y is a single bond, an oxygen atom or a sulfur atom; and E is -CO 2 H, -CO 2 P, with P representing alkyl, proxetil or medoxomil, or bioisostere of a carboxyl group represented by hydroxamic acid (-CO-NH-OH), sulfonamide (-NH-SO 2 -C 1 ∼C 6 alkyl), acylcyanamide (-CO-NH-CN), acylsulfonamide (-CO-NH-SO 2 -C 1 ∼C 6 alkyl, -SO 2 -NH-CO-C 1 ∼C 6 alkyl), tetrazolyl, oxadiazolonyl, oxadiazolthionyl, oxathiadiazolyl, thiadiazolonyl, triazolthionyl, and hydroxyisoxazolyl]. [wherein ring A is a cyclohexyl substituted by E at the 4-position or a phenyl substituted by E at the 4-position; ring B is cycloalkyl, aryl or heteroaryl; m is an integer of any one of 0∼2; n is an integer of any one of 1∼3; R 1 is a hydrogen atom, a C 1 ∼C 4 alkyl group, a C 1 ∼C 4 alkoxy group, a halogen atom, or a C 1 ∼C 4 haloalkyl group; R 2 and R 3 are each independently a hydrogen atom, a halogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the carbon atom to which R 2 and R 3 are adjacent, form a C 3 ∼C 6 carbon ring; R 4 and R 5 are each independently a hydrogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the carbon atom to which R 4 and R 5 are adjacent, form a C 3 ∼C 6 carbon ring, and R 6 and R 7 are each independently a hydrogen atom, a C 1 ∼C 4 alkyl group, a C 1 ∼C 4 alkoxy group, a C 1 ∼C 4 hydroxyalkyl group, a carboxyl group, a cyano group, a halogen atom, a C 1 ∼C 4 haloalkyl group, or a C 1 ∼C 4 haloalkoxy group; X is -OR 8, -NR 9 R 10 or a halogen atom; R 8 is a hydrogen atom, a C 1 ∼C 4 alkyl group or a C 1 ∼C 4 haloalkyl group; R 9 and R 10 are each independently a hydrogen atom or a C 1 ∼C 4 alkyl group or may, taken together with the nitrogen atom to which R 9 and R 10 are adjacent, form a nitrogen-containing heterocycle, Y is a single bond, an oxygen atom or a sulfur atom; and E is -CO 2 H, -CO 2 P, with P representing alkyl, proxetil or medoxomil, or bioisostere of a carboxyl group represented by hydroxamic acid (-CO-NH-OH), sulfonamide (-NH-SO 2 -C 1 ∼C 6 alkyl), acylcyanamide (-CO-NH-CN), acylsulfonamide (-CO-NH-SO 2 -C 1 ∼C 6 alkyl, -SO 2 -NH-CO-C 1 ∼C 6 alkyl), tetrazolyl, oxadiazolonyl, oxadiazolthionyl, oxathiadiazolyl, thiadiazolonyl, triazolthionyl, and hydroxyisoxazolyl].